

IN THE CLAIMS:

Please cancel claims 23 and 24 without prejudice or disclaimer, and amend claims 1-3, 5-7, 10-13, and 25-29 as follows:

1. (Amended twice) A compound comprising [containing] an antigen binding region linked [which is bound] to at least one prodrug-activating enzyme, where the antigen binding region is composed of a single polypeptide chain, and where the antigen binding region has a bivalent or a multivalent structure.

2. (Amended) A compound as claimed in claim 1, wherein the compound comprises [carries] covalently bonded carbohydrates.

3. (Amended) A compound as claimed in claim 1, wherein the antigen binding region comprises [contains] a variable domain of a heavy antibody chain and a variable domain of a light antibody chain (sFv fragment).

5. (Amended twice) A compound as claimed in claim 4 [3], wherein the TAA is selected from the group consisting [essentially] of an N-CAM, PEM, EGF-R, Sialyl-Le^a, Sialyl-Le^x, TF β , GICA, GD₃, GD₂, TAG72, CA125, the 24-25 kDa glycoprotein defined by Mab L6, and CEA.

6. (Amended twice) A compound as claimed in claim 1, wherein the enzyme is selected from the group consisting [essentially] of a lactamase, pyroglutamate aminopeptidase, D-aminopeptidase, oxidase, peroxidase, phosphatase, hydroxynitrile lyase, protease, esterase, carboxypeptidase and glycosidase.

7. (Amended twice) A compound as claimed in claim 1 [6], wherein the enzyme is a β -glucuronidase, which is selected from the group consisting of an E. coli [E. coli] β -glucuronidase, a Kobayasia nipponica [Kobayasia nipponica] β -glucuronidase, a Secale cereale [Secale cereale] β -glucuronidase and a human β -glucuronidase.

10. (Amended twice) A compound as claimed in claim 1, which has undergone [undergoes] secretory expression in Saccharomyces cerevisiae [Saccharomyces cerevisiae] or in Hansenula polymorpha [Hansenula polymorpha].

11. (Amended twice) A compound as claimed in claim 1, which is expressed in E. coli [E. coli] and is subsequently chemically glycosylated.

12. (Amended twice) A compound as claimed in claim 30, wherein the sFv- β -lactamase fusion protein has undergone periplasmic expression in E. coli [E. coli] and is chemically glycosylated.

13. (Amended twice) A compound as claimed in claim 30, wherein the sFv- β -lactamase fusion protein has undergone [undergoes] secretory expression in Saccharomyces cerevisiae [Saccharomyces cerevisiae] or Hansenula polymorpha [Hansenula polymorpha].

25. (Amended) A pharmaceutical composition comprising [containing] a compound as claimed in claim 1 and a physiologically acceptable carrier.

26. A diagnostic aid comprising [containing] a compound as claimed in claim 1.

27. (Amended) A compound as claimed in claim 6, wherein the lactamase enzyme is a Bacillus cereus [Bacillus cereus II] β -lactamase II.

28. (Amended) A compound as claimed in claim 6, wherein the carboxypeptidase enzyme is a carboxypeptidase G2 from Pseudomonas [Pseudomonas].

29. (Amended) A compound as claimed in claim 10, which undergoes secretory expression in Hansenula polymorpha [Hansenula polymorpha].